Importance and limitations of chemotherapy among the available treatments for gastrointestinal tumours

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 2, 2009, Pages 162-184

  Marin, Jose J G ^a,c   Romero, Marta R ^a,b   Blazquez, Alba G ^a   Herraez, Elisa ^a   Keck, Emma ^a   Briz, Oscar ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b MEDICAL RESEARCH COUNCIL   (United Kingdom)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACARBAZINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GLUTATHIONE; HYDROXYUREA; IMATINIB; IRINOTECAN; METHOTREXATE; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SUNITINIB; TEGAFUR; TRASTUZUMAB; UNINDEXED DRUG; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CARCINOGENESIS; CARCINOID; CELL SURVIVAL; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; DIGESTIVE SYSTEM CANCER; DNA REPAIR; DRUG METABOLISM; DRUG SENSITIVITY; DRUG SPECIFICITY; DRUG TARGETING; DRUG UPTAKE; ESOPHAGUS CANCER; HUMAN; LARGE INTESTINE CANCER; LIVER METASTASIS; PANCREAS CANCER; PROTEIN EXPRESSION; REVIEW; SMALL INTESTINE CANCER; STOMACH ADENOCARCINOMA; STOMACH SARCOMA; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GASTROINTESTINAL TUMOR; METABOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GASTROINTESTINAL NEOPLASMS; HUMANS;

EID: 64049097971     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787313828     Document Type: Review

References (315)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics, 2008. CA Cancer J. Clin., 2008, 58, 71-96.
2. Ferlay, J.; Autier, P.; Boniol, M.; Heanue, M.; Colombet, M..; Boyle, P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol., 2007, 18, 581-592.
3. Jass, J.R.; Sobin, L.H.; Watanabe, H. The World Health Organization's histologic classification of gastrointestinal tumors. A commentary on the second edition. Cancer, 1990, 66, 2162-2167.
4. Marin, J.J.G.; Castaño, B.; Martinez-Becerra, P.; Rosales, R.R.; Monte, M.J. Chemotherapy in the treatment of primary liver tumours. Cancer Ther., 2008, 6, 711-728.
5. Hagenbuch, B.; Meier, P.J. Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch., 2004, 447, 653-665.
6. Sai, Y.; Tsuji, A. Transporter-mediated drug delivery: recent progress and experimental approaches. Drug Discov. Today, 2004, 9, 712-720.
7. Ballestero, M.R.; Monte, M.J.; Briz, O.; Jiménez, F.; Gonzalez-San Martin, F.; Marin, J.J. Expression of transporters potentially involved in the targeting of cytostatic bile acid derivatives to colon cancer and polyps. Biochem. Pharmacol., 2006, 72, 729-738.
8. Nozawa, T.; Minami, H.; Sugiura, S.; Tsuji, A.; Tamai, I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos., 2005, 33, 434-439.
9. Abe, T.; Unno, M.; Ongawa, T.; Tokui, T.; Kondo, T.N.; Nakagomi, R.; Adachi, H.; Fujiwara, K.; Okabe, M.; Suzuki, T.; Nunoki, K.; Sato, E.; Kakyo, M.; Nishio, T.; Sugita, J.; Asano, N.; Tanemoto, M.; Seki, M.; Date, F.; Ono, K.; Kondo, Y.; Shiiba, K.; Suzuki, M.; Ohtani, H.; Shimosegawa, T.; Iinuma, K.; Nagura, H.; Ito, S.; Matsuno, S. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology, 2001, 120, 1689-1699.
10. Rothem, L.; Ifergan, I.; Kaufman, Y.; Priest, D.G.; Jansen, G.; Assaraf, Y.G. Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell lines. Biochem. J., 2002, 367, 741-750.
11. White, D.L.; Saunders, V.A.; Dang, P.; Engler, J.; Zannettino, A.C.; Cambareri, A.C.; Quinn, S.R.; Manley, P.W.; Hughes, T.P. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood, 2006, 108, 697-704.
12. Gray, J.H.; Owen, R.P.; Giacomini, K.M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch., 2004, 447, 728-734.
13. Baldwin, S.; Beal, P.; Yao, S.; King, A.; Cass, C.; Young, J. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch., 2004, 447, 735-743.
14. Shin, H.C.; Landowski, C.P.; Sun, D.; Vig B.S.; Kim, I.; Mittal, S.; Lane, M.; Rosania, G.; Drach, J.C.; Amidon, G.L. Functional expression and characterization of a sodium-dependent nucleoside transporter hCNT2 cloned from human duodenum. Biochem. Biophys. Res. Commun., 2003, 307, 696-703.
15. Shin, H.C.; Kim, J.S.; Vig, B.S.; Song, X.; Drach, J.C.; Amidon, G.L. Interaction of intestinal nucleoside transporter hCNT2 with amino acid ester prodrugs of floxuridine and 2-bromo-5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole. Biol. Pharm. Bull., 2006, 29, 247-252.
16. Song, I.S.; Savaraj, N.; Siddik, Z.H.; Liu, P.; Wei, Y.; Wu, C.J.; Kuo, M.T. Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol. Cancer Ther., 2004, 3, 1543-1549.
17. Katano, K.; Kondo, A.; Safaei, R.; Holzer, A.; Samimi, G.; Mishima, M.; Kuo, Y.M.; Rochdi, M.; Howell, S.B. Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. Cancer Res., 2002, 62, 6559-6565.
18. Evans, A.M. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther. Drug Monit., 2000, 22, 131-136.
19. Hunter, J.; Hirst, B.H.; Simmons, N.L. Epithelial secretion of vinblastine by human intestinal adenocarcinoma cell (HCT-8 and T84) layers expressing P-glycoprotein. Br. J. Cancer, 1991, 64, 437-444.
20. Fojo, A.T.; Ueda, K.; Slamon, D.J.; Poplack, D.G.; Gottesman, M.M.; Pastan, I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. USA, 1987, 84, 265-269.
21. Gatmaitan, Z.C.; Arias, I.M. Structure and function of P-glycoprotein in normal liver and small intestine. Adv. Pharmacol., 1993, 24, 77-97.
22. Seithel, A.; Karlsson, J.; Hilgendorf, C.; Björquist, A.; Ungell, AL. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci., 2006, 28, 291-299.
23. Englund, G.; Rorsman, F.; Rönnblom, A.; Karlbom, U.; Lazorova, L.; Gråsjö, J.; Kindmark, A.; Artursson, P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci., 2006, 29, 269-277.
24. Devita, V.T.; Hellman, S.; Rosenberg, S.A. In Important advances in Oncology; Cordon-Cardo, C., O'Brien, J., Eds., Lippencott, Philadelphia, 1991, pp. 19.
25. Wallner, J.; Depisch, D.; Gsur, A.; Götzl, M.; Haider, K; Pirker, R. MDR1 gene expression and its clinical relevance in primary gastric carcinomas. Cancer, 1993, 71, 667-671.
26. Theou, N.; Gil, S.; Devocelle, A.; Julie, C.; Lavergne-Slove, A.; Beauchet, A.; Callard P.; Farinotti, R.; Le Cesne, A.; Lemoine, A.; Faivre-Bonhomme, L.; Emile, J.F. Multidrug resistance proteins in gastrointestinal stromal tumors: site-dependent expression and initial response to imatinib. Clin. Cancer Res., 2005, 11, 7593-7598.
27. Langer, R.; Specht, K.; Becker, K.; Ewald, P.; Ott, K.; Lordick, F.; Siewert, J.R.; Höfler, H. Comparison of pretherapeutic and post-therapeutic expression levels of chemotherapy-associated genes in adenocarcinomas of the esophagus treated by 5-fluorouracil- and cisplatin-based neoadjuvant chemotherapy. Am. J. Clin. Pathol., 2007, 128, 191-197.
28. Lacueva, J.; Perez-Ramos, M.; Soto, J.L.; Oliver, I.; Andrada, E.; Medrano, J.; Perez-Vazquez, T.; Arroyo, A.; Carrato, A.; Ferragut, J.A.; Calpena, R. Multidrug resistance-associated protein (MRP1) gene is strongly expressed in gastric carcinomas. Analysis by immunohistochemistry and real-time quantitative RT-PCR. Histopathology, 2005, 46, 389-395.
29. Tsunoda, S.; Okumura, T.; Ito, T.; Kondo, K.; Ortiz, C.; Tanaka, E.; Watanabe, G.; Itami, A.; Sakai, Y.; Shimada, Y. ABCG2 expression is an independent unfavorable prognostic factor in esophageal squamous cell carcinoma. Oncology, 2006, 71, 251-258.
30. Olempska, M.; Eisenach, P.A.; Ammerpohl, O.; Ungefroren, H.; Fandrich, F.; Kalthoff, H. Detection of tumor stem cell markers in pancreatic carcinoma cell lines. Hepatobiliary Pancreat. Dis. Int., 2007, 6, 92-97.
31. Doyle, L.A.; Ross, D.D. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene, 2003, 22, 7340-7358.
32. Salonga, D.; Danenberg, K.D.; Johnson, M.; Metzger, R.; Groshen, S.; Tsao-Wei, D.D.; Lenz, H.J.; Leichman, C.G.; Leichman, L.; Diasio, R.B.; Danenberg, P.V. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res., 2000, 6, 1322-1327.
33. Uchida, K.; Hayashi, K.; Kuramochi, H.; Takasaki, K. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Int. J. Oncol., 2001, 19, 341-346.
34. Schwartz, E.L.; Baptiste, N.; Wadler, S.; Makower, D. Thymidine phosphorylase mediates the sensitivity of human colon carcinoma cells to 5-fluorouracil. J. Biol. Chem., 1995, 270, 19073-19077.
35. Ishikawa, T.; Ali-Osman, F. Glutathione-associated cis-diammine-dichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. J. Biol. Chem., 1993, 268, 20116-20125.
36. Kodera, Y.; Isobe, K.; Yamauchi, M.; Kondo, K.; Akiyama, S.; Ito, K.; Nakashima, I.; Takagi, H. Expression of glutathione-S-transferases alpha and pi in gastric cancer: a correlation with cisplatin resistance. Cancer Chemother. Pharmacol., 1994, 34, 203-208.
37. Okuyama, T.; Maehara, Y.; Endo, K.; Baba, H.; Adachi, Y.; Kuwano, M.; Sugimachi, K. Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer, 1994, 74, 1230-1236.
38. Kelland, L.R. New platinum antitumor complexes. Crit. Rev. Oncol. Hematol., 1993, 15, 191-219.
39. Chao, C.C.; Huang, Y.T.; Ma, C.M.; Chou, W.Y.; Lin-Chao, S. Overexpression of glutathione S-transferase and elevation of thiol pools in a multidrug-resistant human colon cancer cell line. Mol. Pharmacol., 1992, 41, 69-75.
40. Zhang, J.; Ji, J.; Ji, Y.B.; Yuan, F.; Liu, B.Y.; Zhu, Z.G.; Lin, Y.Z. Antitumor effects of chemotherapeutic drugs on fresh human gastric cancer cells and their relationships to expressions of P-glycoprotein and glutathione S transferase-pi. Ai Zheng, 2005, 24, 432-437.
41. Sato, K.; Tsuchida, S.; Tamai, K. Anti-cancer drug resistance and glutathione S-transferases. Gan To Kagaku Ryoho, 1989, 16, 592-598.
42. Takahashi, Y.; Niitsu, Y. Glutathione S transferases-pi. Gan To Kagaku Ryoho, 1994, 21, 945-951.
43. Shimoda, R.; Achanzar, W.E.; Qu, W.; Nagamine, T.; Takagi, H.; Mori, M.; Waalkes, M.P. Metallothionein is a potential negative regulator of apoptosis. Toxicol. Sci., 2003, 73, 294-300.
44. Kelley, S.L.; Basu, A.; Teicher, B.A.; Hacker, M.P.; Hamer, D.H.; Lazo J.S. Overexpression of metallothionein confers resistance to anticancer drugs. Science, 1988, 241, 1813-1815.
45. Hishikawa, Y.; Abe, S.; Kinugasa, S.; Yoshimura, H.; Monden, N.; Igarashi, M.; Tachibana, M.; Nagasue, N. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. Oncology, 1997, 54, 342-347.
46. Chun, J.H.; Kim, H.K.; Kim, E.; Kim, I.H.; Kim, J.H.; Chang, H.J.; Choi, I.J.; Lim, H.S.; Kim, I.J.; Kang, H.C.; Park, J.H.; Bae, J.M.; Park, J.G. Increased expression of metallothionein is associated with irinotecan resistance in gastric cancer. Cancer Res., 2004, 64, 4703-4706.
47. Janssen, A.M.; van Duijn, W.; Kubben, F.J.; Griffioen, G.; Lamers, C.B.; van Krieken, J.H.; van de Velde, C.J.; Verspaget, H.W. Prognostic significance of metallothionein in human gastrointestinal cancer. Clin. Cancer Res., 2002, 8, 1889-1896.
48. Tuccari, G.; Giuffrè, G.; Arena, F.; Barresi, G. Immunohistochemical detection of metallothionein in carcinomatous and normal human gastric mucosa. Histol. Histopathol., 2000, 15, 1035-1041.
49. Galizia, G.; Ferraraccio, F.; Lieto, E.; Orditura, M.; Castellano, P.; Imperatore, V.; La Manna, G.; Pinto, M.; Ciardiello, F.; La Mura, A.; De Vita, F. p27 downregulation and metallothionein overexpression in gastric cancer patients are associated with a poor survival rate. J. Surg. Oncol., 2006, 93, 241-252.
50. Kamoshida, S.; Suzuki, M.; Sakurai, Y.; Ochiai, M.; Kimura, F.; Kuwao, S.; Sakamoto, K.; Sugimoto, Y.; Fukushima, M.; Tsutsumi, Y. Expression of chemoresistance-related proteins in alpha-fetoprotein-producing adenocarcinoma of the digestive organs. Oncol. Rep., 2006, 16, 721-727.
51. Burchell, B.; Baird, S.; Coughtrie, M.W. The role of xenobiotic glucuronidating enzymes in drug resistance of tumour tissues and cells. Princess Takamatsu Symp., 1990, 21, 263-275.
52. Xu, Y.; Villalona-Calero, M.A. Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol., 2002, 13, 1841-1851.
53. Cummings, J.; Ethell, B.T.; Jardine, L.; Boyd, G.; Macpherson, J.S.; Burchell, B.; Smyth, J.F.; Jodrell, D.I. Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives. Cancer Res., 2003, 63, 8443-8450.
54. Cummings, J.; Ethell, B.T.; Jardine, L.; Burchell, B. Glucuronidation of SN-38 and NU/ICRF 505 in human colon cancer and adjacent normal colon. Anticancer Res., 2006; 26, 2189-2196.
55. Iqbal, S.; Lenz, H.J. Determinants of prognosis and response to therapy in colorectal cancer. Curr. Oncol. Rep., 2001, 3, 102-108.
56. Fakhrejahani, E.; Miyamoto, A.; Tanigawa, N. Correlation between thymidylate synthase and dihydropyrimidine dehydrogenase mRNA level and in vitro chemosensitivity to 5-fluorouracil, in relation to differentiation in gastric cancer. Cancer Chemother. Pharmacol., 2007, 60, 437-446.
57. Johnston, P.G.; Lenz, H.J.; Leichman, C.G.; Danenberg, K.D.; Allegra, C.J.; Danenberg, P.V.; Leichman, L. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res., 1995, 55, 1407-1412.
58. Soong, R.; Shah, N.; Salto-Tellez, M.; Tai, B.C.; Soo, R.A.; Han, H.C.; Ng, S.S.; Tan, W.L.; Zeps, N.; Joseph, D.; Diasio, R.B.; Iacopetta, B. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann. Oncol., 2008, 19, 915-919.
59. Jansen, W.J.; Kolfschoten, G.M.; Erkelens, C.A.; Van Ark-Otte, J.; Pinedo, H.M.; Boven, E. Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma. Int. J. Cancer, 1997, 73, 891-896.
60. Boyer, J.; McLean, E.G.; Aroori, S.; Wilson, P.; McCulla, A.; Carey, P.D.; Longley, D.B.; Johnston, P.G. Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan. Clin. Cancer Res., 2004, 10, 2158-2167.
61. Rubin, B.P. Gastrointestinal stromal tumours: an update. Histopathology, 2006, 48, 83-96.
62. Heinrich, M.C.; Corless, C.L.; Demetri, G.D.; Blanke, C.D.; von Mehren, M.; Joensuu, H.; McGreevey, L.S.; Chen, C.J.; van den Abbeele, A.D.; Druker, B.J.; Kiese, B.; Eisenberg, B.; Roberts, P.J.; Singer, S.; Fletcher, C.D.; Silberman, S.; Dimitrijevic, S.; Fletcher, J.A. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol., 2003, 21, 4342-4349.
63. Mol, C.D.; Dougan, D.R.; Schneider, T.R.; Skene, R.J.; Kraus, M.L.; Scheibe, D.N.; Snell, G.P.; Zou, H.; Sang, B.C.; Wilson, K.P. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem., 2004, 279, 31655-31663.
64. Poklar, N.; Pilch, D.S.; Lippard, S.J.; Redding, E.A.; Dunham, S.U.; Breslauer, K.J. Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc. Natl. Acad. Sci. USA, 1996, 93, 7606-7611.
65. Lee, K.B.; Parker, R.J.; Bohr, V.; Cornelison, T.; Reed, E. Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3. Carcinogenesis, 1993, 14, 2177-2180.
66. Melton, D.W.; Ketchen, A.M.; Nunez, F.; Bonatti-Abbondandolo, S.; Abbondandolo, A.; Squires, S.; Johnson, R.T. Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. J. Cell Sci., 1998, 111, 395-404.
67. Youn, C.K.; Kim, M.H.; Cho, H.J.; Kim, H.B.; Chang, I.Y.; Chung, M.H.; You, H.J. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res., 2004, 64, 4849-4857.
68. Arnould, S.; Hennebelle, I.; Canal, P.; Bugat, R.; Guichard, S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur. J. Cancer, 2003, 39, 112-119.
69. Joshi, M.B.; Shirota, Y.; Danenberg, K.D.; Conlon, D.H.; Salonga, D.S.; Herndon, J.E.; Danenberg, P.V.; Harpole, D.H. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin. Cancer Res., 2005, 11, 2215-2221.
70. Kwon, H.C.; Roh, M.S.; Oh, S.Y.; Kim, S.H.; Kim, M.C.; Kim, J.S.; Kim, H.J. Prognostic value of expression of ERCC1, thymidylate synthase, and glutathione S-transferase P1 for 5-fluorouracil/oxaliplatin chemotherapy in advanced gastric cancer. Ann. Oncol., 2007, 18, 504-509.
71. Bevilacqua, R.A.; Simpson A.J. Methylation of the hMLH1 promoter but no hMLH1 mutations in sporadic gastric carcinomas with high-level microsatellite instability. Int. J. Cancer, 2000, 87, 200-203.
72. Farrington, S.M.; Lin-Goerke, J.; Ling, J.; Wang, Y.; Burczak, J.D.; Robbins, D.J.; Dunlop, M.G. Systematic analysis of hMSH2 and hMLH1 in young colon cancer patients and controls. Am. J. Hum. Genet., 1998, 63, 749-759.
73. Thibodeau, S.N.; French, A.J.; Cunningham, J.M.; Tester, D.; Burgart, L.J.; Roche, P.C.; McDonnell, S.K.; Schaid, D.J.; Vockley, C.W.; Michels, V.V.; Farr, G.H. Jr.; O'Connell, M.J. Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res., 1998, 58, 1713-1718.
74. Lipkin, S.M.; Wang. V.; Stoler, D.L.; Anderson, G.R.; Kirsch, I.; Hadley, D.; Lynch, H.T.; Collins, F.S. Germline and somatic mutation analyses in the DNA mismatch repair gene MLH3: Evidence for somatic mutation in colorectal cancers. Hum. Mutat., 2001, 17, 389-396.
75. Watanabe, Y.; Koi, M.; Hemmi, H.; Hoshai, H.; Noda, K. A change in microsatellite instability caused by cisplatin-based chemotherapy of ovarian cancer. Br. J. Cancer, 2001, 85, 1064-1069.
76. Brown, R.; Hirst, G.L.; Gallagher, W.M.; McIlwrath, A.J.; Margison, G.P.; van der Zee, A.G.; Anthoney, D.A. hMLH1 expression and cellular responses of ovarian tumour cells to treatment with cytotoxic anticancer agents. Oncogene, 1997, 15, 45-52.
77. Meyers, M.; Wagner, M.W.; Hwang, H.S.; Kinsella, T.J.; Boothman, D.A. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res., 2001, 61, 5193-5201.
78. Liu, A.; Yoshioka, K.I.; Salerno, V.; Hsieh, P. LC3, an auto-phagosome marker, is highly expressed in gastrointestinal cancers. J. Cell Biochem., 2008, 105, 245-248.
79. Magrini, R.; Bhonde, M.R.; Hanski, M.L.; Notter, M.; Scherubl, H.; Boland, C.R.; Zeitz, M.; Hanski, C. Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int. J. Cancer, 2002, 101, 23-31.
80. Arango, D.; Mariadason, J.M.; Wilson, A.J.; Yang, W.; Corner, G.A.; Nicholas, C.; Aranes, M.J.; Augenlicht, L.H. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br. J. Cancer, 2003, 89, 1757-1765.
81. Bressin, C.; Bourgarel-Rey, V.; Carré, M.; Pourroy, B.; Arango, D.; Braguer, D.; Barra, Y. Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine. Anticancer Drugs, 2006, 17, 181-187.
82. Funato, T.; Kozawa, K.; Kaku, M.; Sasaki, T. Modification of the sensitivity to cisplatin with c-myc over-expression or down-regulation in colon cancer cells. Anticancer Drugs, 2001, 12, 829-834.
83. Longley, D.B.; Boyer, J.; Allen, W.L.; Latif, T.; Ferguson, P.R.; Maxwell, P.J. McDermott, U.; Lynch, M.; Harkin, D.P.; Johnston, P.G. The role of thymidylate synthase induction in modulating p53-regulated gene expression in response to 5-fluorouracil and antifolates. Cancer Res., 2002, 62, 2644-2649.
84. Bunz, F.; Hwang, P.M.; Torrance, C.; Waldman, T.; Zhang, Y.; Dillehay, L.; Williams, J.; Lengauer, C.; Kinzler, K.W.; Vogelstein, B. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J. Clin. Invest., 1999, 104, 263-269.
85. Giovannetti, E.; Backus, H.H.; Wouters, D.; Ferreira, C.G.; van Houten, V.M.; Brakenhoff, R.H.; Poupon, M.F.; Azzarello, A.; Pinedo, H.M.; Peters, G.J. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br. J. Cancer, 2007, 96, 769-775.
86. Liang, J.T.; Huang, K.C.; Cheng, Y.M; Hsu, H.C.; Cheng, A.L.; Hsu, C.H.; Yeh, K.H.; Wang, S.M.; Chang, K.J. P53 overexpression predicts poor chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV colorectal cancers after palliative bowel resection. Int. J. Cancer, 2002, 97, 451-457.
87. Briz, O.; Macias, R.I.R.; Vallejo, M.; Silva, A.; Serrano, M.A.; Marin, J.J.G. Usefulness of liposomes loaded with cytostatic bile acid derivatives to circumvent chemotherapy resistance of enterohepatic tumors. Mol. Pharmacol., 2003, 63, 742-750.
88. Arango, D.; Wilson, A.J.; Shi, Q.; Corner, G.A.; Arañes, M.J.; Nicholas, C.; Lesser, M.; Mariadason, J.M.; Augenlicht, L.H. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer, 2004, 91, 1931-1946.
89. Seo, Y.R.; Chen, E.I.; Smith, M.L. Sensitivity of p53-deficient cells to oxaliplatin and thio-TEPA (N, N′, N″ triethylenethiophosphoramide). Breast Cancer Res. Treat., 2002, 72, 255-263.
90. Longley, D.B.; Wilson, T.R.; McEwan, M.; Allen, W.L.; McDermott, U.; Galligan, L.; Johnston, P.G. c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene, 2006, 25, 838-848.
91. Wilson, T.R.; Longley, D.B.; Johnston, P.G. Chemoresistance in solid tumours. Ann. Oncol., 2006, 17, 315-324.
92. Dart, D.A.; Picksley, S.M.; Cooper, P.A.; Double, J.A.; Bibby, M.C. The role of p53 in the chemotherapeutic responses to cisplatin, doxorubicin and 5-fluorouracil treatment. Int. J. Oncol., 2004, 24, 115-125.
93. Ryu, B.K.; Lee, M.G.; Chi, S.G.; Kim, Y.W.; Park, J.H. Increased expression of cFLIP(L) in colonic adenocarcinoma. J. Pathol., 2001, 194, 15-19.
94. Zhou, X.D.; Yu, J.P.; Liu, J.; Luo, H.S.; Cen, H.X.; Yu, H.G. Overexpression of cellular FLICE-inhibitory protein (FLIP) in gastric adenocarcinoma. Clin. Sci., 2004, 106, 397-405.
95. Anguiano-Hernandez, Y.M.; Chartier, A.; Huerta, S. Smac/DIABLO and colon cancer. Anticancer Agents Med Chem., 2007, 7, 467-473.
96. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature, 2001, 411, 355-365.
97. Ciardiello, F.; Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res., 2001, 7, 2958-2970.
98. Moroni, M.; Veronese, S.; Benvenuti, S.; Marrapese, G.; Sartore-Bianchi, A.; Di Nicolantonio, F.; Gambacorta, M.; Siena, S.; Bardelli, A. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol., 2005, 6, 279-286.
99. Lievre, A.; Bachet, J.B.; Le Corre, D.; Boige, V.; Landi, B.; Emile, J.F.; Cote, J.F.; Tomasic, G.; Penna, C.; Ducreux, M.; Rougier, P.; Penault-Llorca, F.; Laurent-Puig, P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res., 2006, 66, 3992-3995.
100. Han, Z.; Hong, L.; Han, Y.; Wu, K.; Han, S.; Shen, H.; Li, C.; Yao, L.; Qiao, T.; Fan, D. Phospho Akt mediates multidrug resistance of gastric cancer cells through regulation of P-gp, Bcl-2 and Bax. J. Exp. Clin. Cancer Res., 2007, 26, 261-268.
101. Liu, S.Q.; Yu, J.P.; Yu, H.G.; Lv, P.; Chen, H.L. Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells. Dig. Liver Dis., 2006, 38, 310-318.
102. Zhao, Y.; Shen, S.; Guo, J.; Chen, H.; Greenblatt, D.Y.; Kleeff, J.; Liao, Q.D.; Chen, G.; Friess, H.; Leung, P.S. Mitogen-activated protein kinases and chemoresistance in pancreatic cancer cells. J. Surg. Res., 2006, 136, 325-335.
103. Chuang, S.E.; Yeh, P.Y., Lu, Y.S.; Lai, G.M.; Liao, C.M.; Gao, M.; Cheng, A.L. Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem. Pharmacol., 2002, 63, 1709-1716.
104. Arlt, A.; Gehrz, A.; Müerköster, S.; Vorndamm, J.; Kruse, M.L.; Fölsch, U.R.; Schäfer, H. Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death. Oncogene, 2003, 22, 3243-3251.
105. Camp, E.R.; Li, J.; Minnich, D.J.; Brank, A.; Moldawer, L.L.; MacKay, S.L.; Hochwald, S.N. Inducible nuclear factor-kappaB activation contributes to chemotherapy resistance in gastric cancer. J. Am. Coll. Surg., 2004, 199, 249-258.
106. Spychalski, M.; Dziki, L.; Dziki, A. Chemoprevention of colorectal cancer - a new target needed? Colorectal Dis., 2007, 9, 397-401.
107. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA Cancer J. Clin., 2005, 55, 74-108.
108. Pohl, H.; Welch, H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst., 2005, 97, 142-146.
109. Daly, J.M.; Fry, W.A.; Little, A.G.; Winchester, D.P.; McKee, R.F.; Stewart, A.K.; Fremgen, A.M. Esophageal cancer: results of an American College of Surgeons Patient Care Evaluation Study. J. Am. Coll. Surg., 2000, 190, 562-572.
110. Tanaka, S.; Hirabayashi, Y. International comparisons of cumulative risk of oesophagus cancer, from cancer incidence in five continents Vol. VIII. Jpn. J. Clin. Oncol., 2006, 36, 609-610.
111. Siewert, J.R.; Stein, H.J.; Feith, M.; Bruecher, B.L.; Bartels, H.; Fink, U. Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann. Surg., 2001, 234, 360-367.
112. Osborn, N.K.; Keate, R.F.; Trastek, V.F.; Nguyen, C.C. Verrucous carcinoma of the esophagus: clinicopathophysiologic features and treatment of a rare entity. Dig. Dis. Sci., 2003, 48, 465-474.
113. Liberale, G.; De Simone, P.; Snoeck, R.; Féron, P.; Gelin, M.; El Nakadi, I. Verrucous carcinoma of the esophagus. A case report. Minerva Chir., 2005, 60, 61-65.
114. Yachida, S.; Nakanishi, Y.; Shimoda, T.; Nimura, S.; Igaki, H.; Tachimori, Y.; Kato, H. Adenosquamous carcinoma of the esophagus. Clinicopathologic study of 18 cases. Oncology, 2004, 66, 218-225.
115. Fegelman, E.; Law, S.Y.; Fok, M.; Lam, K.Y.; Loke, S.L.; Ma, L.T.; Wong, J. Squamous cell carcinoma of the esophagus with mucin-secreting component. Mucoepidermoid carcinoma. J. Thorac. Cardiovasc. Surg., 1994, 107, 62-67.
116. Hagiwara, N.; Tajiri, T.; Tajiri, T.; Miyashita, M.; Sasajima, K.; Makino, H.; Matsutani, T.; Tsuchiya, Y.; Takubo, K.; Yamashita, K. Biological behavior of mucoepidermoid carcinoma of the esophagus. J. Nippon. Med. Sch., 2003, 70, 401-407.
117. Karaoglanoglu, N.; Eroglu, A.; Turkyilmaz, A.; Gursan, N. Oesophageal adenoid cystic carcinoma and its management options. Int. J. Clin. Pract., 2005, 59, 1101-1103.
118. Tsang, W.Y.; Chan, J.K.; Lee, K.C.; Leung, A.K.; Fu, Y.T. Basaloid-squamous carcinoma of the upper aerodigestive tract and so-called adenoid cystic carcinoma of the oesophagus: the same tumour type? Histopathology, 1991, 19, 35-46.
119. Koury, J.; Vossough, S.; Choe, J.K.; Kim, S.H. Polypoid spindle cell carcinoma of the esophagus. Am. Surg., 2007, 73, 67-69.
120. Rahili, A.; D'Amata, G.; Avallone, S.; Piche, M.; Benchimol, D. Concomitant leiomyoma and leiomyosarcoma of the oesophagus. J. Exp. Clin. Cancer Res., 2005, 24, 487-491.
121. Choh, J.H.; Khazei, A.H.; Ihm, H.J. Leiomyosarcoma of the esophagus: report of a case and review of the literature. J. Surg. Oncol., 1986, 32, 223-226.
122. Lin, C.H.; Hsu, C.W.; Chiang, Y.J.; Ng, K.F.; Chiu, C.T. Esophageal and gastric Kaposi's sarcomas presenting as upper gastrointestinal bleeding. Chang Gung Med. J., 2002, 25, 329-333.
123. Hashibe, M.; Boffetta, P.; Janout, V.; Zaridze, D.; Shangina, O.; Mates, D.; Szeszenia-Dabrowska, N.; Bencko, V.; Brennan, P. Esophageal cancer in Central and Eastern Europe: tobacco and alcohol. Int. J. Cancer, 2007, 120, 1518-1522.
124. Enzinger, P.C.; Mayer, R.J. Esophageal cancer. N. Engl. J. Med., 2003, 349, 2241-2252.
125. Stein, H.J.; Feith, M.; Bruecher, B.L.; Naehrig, J.; Sarbia, M.; Siewert, J.R. Early esophageal cancer: pattern of lymphatic spread and prognostic factors for long-term survival after surgical resection. Ann. Surg., 2005, 242, 566-573.
126. Gammon, M.D.; Schoenberg, J.B.; Ahsan, H.; Risch, H.A.; Vaughan, T.L.; Chow, W.H.; Rotterdam, H.; West, A.B.; Dubrow, R.; Stanford, J.L.; Mayne, S.T.; Farrow, D.C.; Niwa, S.; Blot. W.J.; Fraumeni, J.F.Jr. Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J. Natl. Cancer Inst., 1997, 89, 1277-1284.
127. Freedman, N.D.; Abnet, C.C.; Leitzmann, M.F.; Mouw, T.; Subar, A.F.; Hollenbeck, A.R.; Schatzkin, A. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am. J. Epidemiol., 2007, 165, 1424-1433.
128. Wang, G.Q.; Abnet, C.C.; Shen, Q.; Lewin, K.J.; Sun, X.D.; Roth, M.J.; Qiao, Y.L.; Mark, S.D.; Dong, Z.W.; Taylor, P.R.; Dawsey, S,M. Histological precursors of oesophageal squamous cell carcinoma: results from a 13 year prospective follow up study in a high risk population. Gut, 2005, 54, 187-192.
129. Dry, S.M.; Lewin, K.J. Esophageal squamous dysplasia. Semin. Diagn. Pathol., 2002, 19, 2-11.
130. Lagergren, J.; Bergström, R.; Lindgren, A.; Nyrén, O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med., 1999, 340, 825-831.
131. Pera, M.; Manterola, C.; Vidal, O.; Grande, L. Epidemiology of esophageal adenocarcinoma. J. Surg. Oncol., 2005, 92, 151-159.
132. Lagergren, J. Etiology and risk factors for oesophageal adenocarcinoma: possibilities for chemoprophylaxis? Best Pract. Res. Clin. Gastroenterol., 2006, 20, 803-812.
133. Ye, W.; Held, M.; Lagergren, J.; Engstrand, L.; Blot, W.J.; McLaughlin, J.K.; Nyrén, O. Helicobacter pylori infection and gastric atrophy: risk of adenocarcinoma and squamous-cell carcinoma of the esophagus and adenocarcinoma of the gastric cardia. J. Natl. Cancer Inst., 2004, 96, 388-396.
134. de Castro Carpeño, J.; Gonzalez Baron, M.; Feliu Batlle, J. In Oncología Clínica. Patología especial.; Gonzalez Baron, M., Ordoñez, A., Feliu, J., Zamora, P., Espinosa, E., de Canto, J. Eds., McGraw-Hill Interamericana: Spain, 1998, pp. 111-131.
135. Lerut, T.; Coosemans, W.; De Leyn, P.; Van Raemdonck, D.; Deneffe, G.; Decker, G. Treatment of esophageal carcinoma. Chest, 1999, 116, 463-465.
136. Kelsen, D.P.; Bains, M.; Burt, M. Neoadjuvant chemotherapy and surgery of cancer of the esophagus. Semin. Surg. Oncol., 1990, 6, 268-273.
137. Rusch, V.W.; Levine, D.S.; Haggitt, R.; Reid, B.J. The management of high grade dysplasia and early cancer in Barrett's esophagus. A multidisciplinary problem. Cancer, 1994, 74, 1225-1229.
138. Heitmiller, R.F.; Redmond, M.; Hamilton, S.R. Barrett's esophagus with high-grade dysplasia. An indication for prophylactic esophagectomy. Ann. Surg., 1996, 224, 66-71.
139. Earlam, R.; Cunha-Melo, J.R. Oesophogeal squamous cell carcinoms: II. A critical view of radiotherapy. Br. J. Surg., 1980, 67, 457-461.
140. Whittington, R.; Coia, L.R.; Haller, D.G.; Rubenstein, J.H.; Rosato, E.F. Adenocarcinoma of the esophagus and esophago-gastric junction: the effects of single and combined modalities on the survival and patterns of failure following treatment. Int. J. Radiat. Oncol. Biol. Phys., 1990, 19, 593-603.
141. Lightdale, C.J.; Heier, S.K.; Marcon, N.E.; McCaughan, J.S.; Gerdes, H.; Overholt, B.F.; Sivak, M.V.; Stiegmann, G.V.; Nava, H.R. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest. Endosc., 1995, 42, 507-512.
142. Seewald, S.; Ang, T.L.; Groth, S.; Zhong, Y.; Bertschinger, P.; Altorfer, J.; Thonke, F.; Soehendra, N. Detection and endoscopic therapy of early esophageal adenocarcinoma. Curr. Opin. Gastroenterol., 2008, 24, 521-529.
143. Enzinger, P.C.; Ilson, D.H.; Kelsen, D.P. Chemotherapy in esophageal cancer. Semin. Oncol., 1999, 26, 12-20.
144. Ross, P.; Nicolson, M.; Cunningham, D.; Valle, J.; Seymour, M.; Harper, P.; Price, T.; Anderson, H.; Iveson, T.; Hickish, T.; Lofts, F.; Norman, A. Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J. Clin. Oncol., 2002, 20, 1996-2004.
145. Taïeb, J.; Artru, P.; Baujat, B.; Mabro, M.; Carola, E.; Maindrault, F.; Tournigand, C.; Krulik, M.; Louvet, C.; de Gramont, A. Optimisation of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of hydroxyurea, leucovorin, 5-FU and cisplatin (HLFP regimen) for metastatic oesophageal cancer. Eur. J. Cancer, 2002, 38, 661-666.
146. Kelsen, D.P.; Cvitkovic, E.; Bains, M.; Shils, M.; Howard, J.; Hopfan, S.; Golbey, R.B. cis-Dichlorodiammineplatinum(II) and bleomycin in the treatment of esophageal carcinomas. Cancer Treat. Rep., 1978, 62, 1041-1046.
147. Conroy, T.; Etienne, P.L.; Adenis, A.; Ducreux, M.; Paillot, B.; Oliveira, J.; Seitz, J.F.; Francois, E.; Van Cutsem, E.; Wagener, D.J.; Kohser, F.; Daamen, S.; Praet, M.; Gorlia, T.; Baron, B.; Wils, J. Vinorelbine and cisplatin in metastatic squamous cell carcinoma of the oesophagus: response, toxicity, quality of life and survival. Ann. Oncol., 2002, 13, 721-729.
148. Ajani, J.A.; Komaki, R.; Putnam, J.B.; Walsh, G.; Nesbitt, J.; Pisters, P.W.; Lynch, P.M.; Vaporciyan, A.; Smythe, R.; Lahoti, S.; Raijman, I.; Swisher, S.; Martin, F.D.; Roth, J.A. A three-step strategy of induction chemotherapy then chemoradiation followed by surgery in patients with potentially resectable carcinoma of the esophagus or gastroesophageal junction. Cancer, 2001, 92, 279-286.
149. Höfler, H.; Langer, R.; Ott, K.; Keller, G. Prediction of response to neoadjuvant chemotherapy in carcinomas of the upper gastrointestinal tract. Adv. Exp. Med. Biol., 2006, 587, 115-120.
150. Langer, R.; Specht, K.; Becker, K.; Ewald, P.; Bekesch, M.; Sarbia, M.; Busch, R.; Feith, M.; Stein, H.J.; Siewert, J.R.; Höfler, H. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin. Cancer Res., 2005, 11, 7462-7469.
151. Gu, Z.D.; Li, J.Y.; Li, M.; Gu, J.; Shi, X.T.; Ke, Y.; Chen, K.N. Matrix metalloproteinases expression correlates with survival in patients with esophageal squamous cell carcinoma. Am. J. Gastroenterol., 2005, 100, 1835-1843.
152. Lochhead, P.; El-Omar, E.M. Gastric cancer. Br. Med. Bull., 2008, 85, 87-100.
153. Parkin, D.M.; Pisani, P.; Ferlay, J. Estimates of the worldwide incidence of 25 major cancers in 1990. Int. J. Cancer, 1999, 80, 827-841.
154. Sipponen, P.; Correa, P. Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hypothesis. Gastric Cancer, 2002, 5, 213-219.
155. Yamamoto, S. Stomach cancer incidence in the world. Jpn. J. Clin. Oncol., 2001, 31, 471.
156. Verdecchia, A.; Corazziari, I.; Gatta, G.; Lisi, D.; Faivre, J.; Forman, D.; EUROCARE Working Group. Explaining gastric cancer survival differences among European countries. Int. J. Cancer, 2004, 109, 737-741.
157. Crew, K.D.; Neugut, A.I. Epidemiology of gastric cancer. World J. Gastroenterol., 2006, 12, 354-362.
158. Jimenez Lacave, A.; Vieitez de Prado, J.M.; Esteban González, E. In Oncología Clínica. Patología especial.; Gonzalez Baron, M., Ordoñez, A., Feliu, J., Zamora, P., Espinosa, E., de Canto, J. Eds., McGraw-Hill Interamericana: Spain, 1998, pp. 133-148.
159. Lauren, P. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol. Microbiol. Scand., 1965, 64, 31-49.
160. McColl, K.E. Cancer of the gastric cardia. Best Pract. Res. Clin. Gastroenterol., 2006, 20, 687-696.
161. Janssen, C.W. Jr.; Maartmann-Moe, H.; Lie, R.T.; Matre, R. Age and sex distribution of intestinal type and diffuse gastric carcinoma. APMIS, 1991, 99, 78-82.
162. Henson, D.E.; Dittus, C.; Younes, M.; Nguyen, H.; Albores-Saavedra, J. Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000: increase in the signet ring cell type. Arch. Pathol. Lab. Med., 2004, 128, 765-770.
163. Siewert, J.R.; Stein, H.J. Classification of adenocarcinoma of the oesophagogastric junction. Br. J. Surg., 1998, 85, 1457-1459.
164. Siewert, J.R.; Feith, M.; Stein, H.J. Biologic and clinical variations of adenocarcinoma at the esophago-gastric junction: relevance of a topographic-anatomic subclassification. J. Surg. Oncol., 2005, 90, 139-146.
165. Kamangar, F.; Dawsey, S.M.; Blaser, M.J.; Perez-Perez, G.I.; Pietinen, P.; Newschaffer, C.J.; Abnet, C.C.; Albanes, D.; Virtamo, J.; Taylor, P.R. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J. Natl. Cancer Inst., 2006, 98, 1445-1452.
166. Swan, R.; Miner, T.J. Current role of surgical therapy in gastric cancer. World J. Gastroenterol., 2006, 12, 372-379.
167. von Rahden, B.H.; Stein, H.J.; Siewert, J.R. Surgical management of esophagogastric junction tumors. World J. Gastroenterol., 2006, 12, 6608-6613.
168. Gunderson, L.L.; Sosin, H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int. J. Radiat. Oncol. Biol. Phys., 1982, 8, 1-11.
169. Green, P.H.; O'Toole, K.M.; Slonim, D.; Wang, T.; Weg, A. Increasing incidence and excellent survival of patients with early gastric cancer: experience in a United States medical center. Am. J. Med., 1988, 85, 658-661.
170. Zhang, X., Watson, D.I.; Jamieson, G.G. Lymph node metastases of adenocarcinoma of the esophagus and esophagogastric junction. Chin. Med. J., 2007, 120, 2268-2270.
171. Allum, W.H.; Hallissey, M.T.; Ward, L.C.; Hockey, M.S. A controlled, prospective, randomised trial of adjuvant chemotherapy or radiotherapy in resectable gastric cancer: interim report. British Stomach Cancer Group. Br. J. Cancer., 1989, 60, 739-744.
172. Valentini, V.; Cellini, F. Radiotherapy in gastric cancer: a systematic review of literature and new perspectives. Expert Rev. Anticancer Ther., 2007, 7, 1379-1393.
173. Rivera, F.; Vega-Villegas, M.E.; Lopez-Brea, M.F. Chemotherapy of advanced gastric cancer. Cancer Treat. Rev., 2007, 33, 315-324.
174. Cen, P.; Ajani, J.A. Medical treatment for advanced gastroesophageal adenocarcinoma. Curr. Opin. Gastroenterol., 2007, 23, 631-635.
175. Cascinu, S.; Labianca, R.; Alessandroni, P.; Marcellini, M.; Silva, R.R.; Pancera, G.; Testa, E.; Martignoni, G.; Barni, S.; Frontini, L.; Zaniboni, A.; Luporini, G.; Cellerino, R.; Catalano, G. Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. J. Clin. Oncol., 1997, 15, 3313-3319.
176. Cunningham, D.; Starling, N.; Rao, S.; Iveson, T.; Nicolson, M.; Coxon, F.; Middleton, G.; Daniel, F.; Oates, J.; Norman, A.R. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N. Engl. J. Med., 2008, 358, 36-46.
177. Ajani, J.A.; Faust, J.; Ikeda, K.; Yao, J.C.; Anbe, H.; Carr, K.L.; Houghton, M.; Urrea, P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J. Clin. Oncol., 2005, 23, 6957-6965.
178. MacDonald, J.S.; Schein, P.S.; Woolley, P.V.; Smythe, T.; Ueno, W.; Hoth, D.; Smith, F.; Boiron, M.; Gisselbrecht, C.; Brunet, R.; Lagarde, C. 5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer. Ann. Intern. Med., 1980, 93, 533-536.
179. Vanhoefer, U.; Rougier, P.; Wilke, H.; Ducreux, M.P.; Lacave, A.J.; Van Cutsem, E.; Planker, M.; Santos, J.G.; Piedbois, P.; Paillot, B.; Bodenstein, H.; Schmoll, H.J.; Bleiberg, H.; Nordlinger, B.; Couvreur, M.L.; Baron, B.; Wils, J.A. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J. Clin. Oncol., 2000, 18, 2648-2657.
180. Roth, A.D.; Herrmann, R.; Morant, R.; Borner, M.M.; Honegger, H.P.; Obrist, R.; Bacchi, M.; Lange, J.; Alberto, P.; Castiglione, M. Cisplatin, doxorubicin and etoposide (PAV) in advanced gastric carcinoma: the SAKK experience. Swiss Group for Clinical Cancer Research (SAKK). Eur. J. Cancer, 1998, 34, 2126-2128.
181. Honecker, F.; Kollmannsberger, C.; Quietzsch, D.; Haag, C.; Schroeder, M.; Spott, C.; Hartmann, J.T.; Baronius, W.; Hempel, V.; Kanz, L.; Bokemeyer, C. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer. Anticancer Drugs, 2002, 13, 497-503.
182. Deeks, E.D.; Scott, L.J. Docetaxel: in gastric cancer. Drugs, 2007, 67, 1893-1901.
183. Shah, M.A.; Ramanathan, R.K.; Ilson, D.H.; Levnor, A.; D'Adamo, D.; O'Reilly, E.; Tse, A.; Trocola, R.; Schwartz, L.; Capanu, M.; Schwartz, G.K.; Kelsen, D.P. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol., 2006, 24, 5201-5206.
184. Giuliani, F.; Gebbia, V.; De Vita, F.; Maiello, E.; Di Bisceglie, M.; Catalano, G.; Gebbia, N.; Colucci, G. Docetaxel as salvage therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico Italia Meridionale (G.O.I.M.). Anticancer Res., 2003, 23, 4219-4222.
185. Koutras, A.K.; Gerolymos, M.K.; Kontogeorgou, E.; Iconomou, G.; Vourli, G.; Tsiata, E.; Makatsoris, T.; Chrysanthopoulos, C.; Kalofonos, H.P. Phase II Study of Irinotecan plus Leucovorin and Bolus 5-Fluorouracil as First- or Second-Line Chemotherapy in Patients with Advanced Gastric or Esophageal-Gastric Junction Adenocarcinoma. J. Chemother., 2007, 19, 724-730.
186. Becker, J.C.; Muller-Tidow, C.; Serve, H.; Domschke, W.; Pohle, T. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J. Gastroenterol., 2006, 12, 3297-3305.
187. Cunningham, D.; Allum, W.H.; Stenning, S.P.; Thompson, J.N.; Van de Velde, C.J.; Nicolson, M.; Scarffe, J.H.; Lofts, F.J.; Falk, S.J.; Iveson, T.J.; Smith, D.B.; Langley, R.E.; Verma, M.; Weeden, S.; Chua, Y.J. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med., 2006, 355, 11-20.
188. Bleiberg, H.; Goffin, J.C.; Dalesio, O.; Buyse, M.; Pector, J.C.; Gignoux, M.; Roussel, A.; Samana, G.; Michel, J.; Gerard, A; Duez, N. Adjuvant radiotherapy and chemotherapy in resectable gastric cancer. A randomized trial of the gastro-intestinal tract cancer cooperative group of the EORTC. Eur. J. Surg. Oncol., 1989, 15, 535-543.
189. Macdonald, J.S.; Smalley, S.R.; Benedetti, J.; Hundahl, S.A.; Estes, N.C.; Stemmermann, G.N.; Haller, D.G.; Ajani, J.A.; Gunderson, L.L.; Jessup, J.M.; Martenson, J.A. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med., 2001, 345, 725-730.
190. Napieralski, R.; Ott, K.; Kremer, M.; Specht, K.; Vogelsang, H.; Becker, K.; Müller, M.; Lordick, F.; Fink, U.; Rüdiger Siewert, J.; Höfler, H.; Keller, G. Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients. Clin. Cancer Res., 2005, 11, 3025-3031.
191. Pidhorecky, I.; Cheney, R.T.; Kraybill, W.G.; Gibbs, J.F. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann. Surg. Oncol., 2000, 7, 705-712.
192. Carson, W.; Karakousis, C.; Douglass, H.; Rao, U.; Palmer, M.L. Results of aggressive treatment of gastric sarcoma. Ann. Surg. Oncol., 1994, 1, 244-251.
193. Gega, M.; Yanagi, H.; Yoshikawa, R.; Noda, M.; Ikeuchi, H.; Tsukamoto, K.; Oshima, T.; Fujiwara, Y.; Gondo, N.; Tamura, K.; Utsunomiya, J.; Hashimoto-Tamaoki, T.; Yamamura, T. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J. Clin. Oncol., 2006, 24, 102-105.
194. Zalupski, M.; Metch, B.; Balcerzak, S.; Fletcher, W.S.; Chapman, R.; Bonnet, J.D.; Weiss, G.R.; Ryan, J.; Benjamin, R.S.; Baker, L.H. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J. Natl. Cancer Inst., 1991, 83, 926-932.
195. Rubin, B.P.; Singer, S.; Tsao, C.; Duensing, A.; Lux, M.L.; Ruiz, R.; Hibbard, M.K.; Chen, C.J.; Xiao, S.; Tuveson, D.A.; Demetri, G.D.; Fletcher, C.D.; Fletcher, J.A. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res., 2001, 61, 8118-8121.
196. Demetri, G.D.; von Mehren, M.; Blanke, C.D.; Van den Abbeele, A.D.; Eisenberg, B.; Roberts, P.J.; Heinrich, M.C.; Tuveson, D.A.; Singer, S.; Janicek, M.; Fletcher, J.A.; Silverman, S.G.; Silberman, S.L.; Capdeville, R.; Kiese, B.; Peng, B.; Dimitrijevic, S.; Druker, B.J.; Corless, C.; Fletcher, C.D.; Joensuu, H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med., 2002, 347, 472-480.
197. Joensuu, H. Second line therapies for the treatment of gastrointestinal stromal tumor. Curr. Opin. Oncol., 2007, 19, 353-358.
198. Heinrich, M.C.; Corless, C.L.; Blanke, C.D.; Demetri, G.D.; Joensuu, H.; Roberts, P.J.; Eisenberg, B.L.; von Mehren, M.; Fletcher, C.D.; Sandau, K.; McDougall, K.; Ou, W.B.; Chen, C.J.; Fletcher, J.A. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J. Clin. Oncol., 2006, 24, 4764-4774.
199. Tamborini, E.; Bonadiman, L.; Greco, A.; Albertini, V.; Negri, T.; Gronchi, A.; Bertulli, R.; Colecchia, M.; Casali, P.G.; Pierotti, M.A.; Pilotti, S. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology, 2004, 127, 294-299.
200. Adsay, N.V.; Basturk, O.; Cheng, J.D.; Andea, A.A. Ductal neoplasia of the pancreas: nosologic, clinicopathologic, and biologic aspects. Semin. Radiat. Oncol., 2005, 15, 254-264.
201. Cervantes, A.; Insa Mollá, A. In Oncología Clínica. Patología especial.; Gonzalez Baron, M., Ordoñez, A., Feliu, J., Zamora, P., Espinosa, E., de Canto, J. Eds., McGraw-Hill Interamericana: Spain, 1998, pp. 149-162.
202. Howard, T.J. Pancreatic adenocarcinoma. Curr. Probl. Cancer, 1996, 20, 281-328.
203. Tonini, G.; Pantano, F.; Vincenzi, B.; Gabbrielli, A.; Coppola, R.; Santini, D. Molecular prognostic factors in patients with pancreatic cancer. Expert Opin. Ther. Targets, 2007, 11, 1553-1569.
204. Lowenfels, A.B.; Maisonneuve, P. Risk factors for pancreatic cancer. J. Cell Biochem., 2005, 95, 649-656.
205. Talamini, G.; Bassi, C.; Falconi, M.; Sartori, N.; Salvia, R.; Rigo, L.; Castagnini, A.; Di Francesco, V.; Frulloni, L.; Bovo, P.; Vaona, B.; Angelini, G.; Vantini, I.; Cavallini, G.; Pederzoli, P. Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Dig. Dis. Sci., 1999, 44, 1303-1311.
206. Reddy, S.K.; Tyler, D.S.; Pappas, T.N.; Clary, B.M. Extended resection for pancreatic adenocarcinoma. Oncologist, 2007, 12, 654-663.
207. Cameron, J.L.; Riall, T.S.; Coleman, J.; Belcher, K.A. One thousand consecutive pancreaticoduodenectomies. Ann. Surg., 2006, 244, 10-15.
208. Sanchez, J.A.; Newman, K.D.; Eichelberger, M.R.; Nauta, R.J. The papillary-cystic neoplasm of the pancreas. An increasingly recognized clinicopathologic entity. Arch. Surg., 1990, 125, 1502-1505.
209. Cervantes-Monteil, F.; Florez-Zorrilla, C.; Alvarez-Martínez, I. Solid-cystic pseudopapillary tumor of the pancreas: acute post-traumatic presentation. Case report and review of the literatura. Rev. Gastroenterol. Mex., 2002, 67, 93-96.
210. Sohn, T.A.; Lillemoe, K.D.; Cameron, J.L.; Huang, J.J.; Pitt, H.A.; Yeo, C.J. Surgical palliation of unresectable periampullary adenocarcinoma in the 1990s. J. Am. Coll. Surg., 1999, 188, 658-666.
211. Reni, M.; Panucci, M.G.; Ferreri, A.J.; Balzano, G.; Passoni, P.; Cattaneo, G.M.; Cordio, S.; Scaglietti, U.; Zerbi, A.; Ceresoli, G.L.; Fiorino, C.; Calandrino, R.; Staudacher, C.; Villa, E.; Di Carlo, V. Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int. J. Radiat. Oncol. Biol. Phys., 2001, 50, 651-658.
212. Tepper, J.E.; Noyes, D.; Krall, J.M.; Sause, W.T.; Wolkov, H.B.; Dobelbower, R.R.; Thomson, J.; Owens, J.; Hanks, G.E. Intraoperative radiation therapy of pancreatic carcinoma: a report of RTOG-8505. Radiation Therapy Oncology Group. Int. J. Radiat. Oncol. Biol. Phys., 1991, 21, 1145-1149.
213. Moertel, C.G.; Frytak, S.; Hahn, R.G.; O'Connell, M.J.; Reitemeier, R.J.; Rubin, J.; Schutt, A.J.; Weiland, L.H.; Childs, D.S.; Holbrook, M.A.; Lavin, P.T.; Livstone, E.; Spiro, H.; Knowlton, A.; Kalser, M.; Barkin, J.; Lessner, H.; Mann-Kaplan, R.; Ramming, K.; Douglas, H.O. Jr; Thomas, P.; Nave, H.; Bateman, J.; Lokich, J.; Brooks, J.; Chaffey, J.; Corson, J.M.; Zamcheck, N.; Novak, J.W. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer, 1981, 48, 1705-1710.
214. Choti, M.A. Adjuvant therapy for pancreatic cancer-the debate continues. N. Engl. J. Med., 2004, 350, 1249-1251.
215. Picozzi, V.J.; Kozarek, R.A.; Traverso, L.W. Interferon-based adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am. J. Surg., 2003, 185, 476-480.
216. Jaffee, E.M.; Hruban, R.H.; Biedrzycki, B.; Laheru, D.; Schepers, K.; Sauter, P.R.; Goemann, M.; Coleman, J.; Grochow, L.; Donehower, R.C.; Lillemoe, K.D.; O'Reilly, S.; Abrams, R.A.; Pardoll, D.M.; Cameron, J.L.; Yeo, C.J. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol., 2001, 19, 145-156.
217. Bruckner, H.W.; Crown, J.; McKenna, A.; Hart, R. Leucovorin and 5-fluorouracil as a treatment for disseminated cancer of the pancreas and unknown primary tumors. Cancer Res., 1988, 48, 5570-5572.
218. Kalser, M.H.; Ellenberg, S.S. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch. Surg., 1985, 120, 899-903.
219. Jacobs, A.D. Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer, 2002, 95, 923-927.
220. Saif, M.W. Is there a standard of care for the management of advanced pancreatic cancer? Highlights from the Gastrointestinal Cancers Symposium. Orlando, FL, USA. January 25-27, 2008. J.O.P., 2008, 9, 91-98.
221. Burris, H.A. 3rd; Moore, M.J.; Andersen, J.; Green, M.R.; Rothenberg, M.L.; Modiano, M.R.; Cripps, M.C.; Portenoy, R.K.; Storniolo, A.M.; Tarassoff, P.; Nelson, R.; Dorr, F.A.; Stephens, C.D.; Von Hoff, D.D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 1997, 15, 2403-2413.
222. Rothenberg, M.L.; Moore, M.J.; Cripps, M.C.; Andersen, J.S.; Portenoy, R.K.; Burris, H.A. 3rd; Green, M.R.; Tarassoff, P.G.; Brown, T.D.; Casper, E.S.; Storniolo, A.M.; Von Hoff, D.D. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol., 1996, 7, 347-353.
223. Duffy, A.; Kortmansky, J.; Schwartz, G.K.; Capanu, M.; Puleio, S.; Minsky, B.; Saltz, L.; Kelsen, D.P.; O'Reilly, E.M. A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma. Ann. Oncol., 2008, 19, 86-91.
224. Safran, H.; Iannitti, D.; Ramanathan, R.; Schwartz, J.D.; Steinhoff, M.; Nauman, C.; Hesketh, P.; Rathore, R.; Wolff, R.; Tantravahi, U.; Hughes, T.M.; Maia, C.; Pasquariello, T.; Goldstein, L.; King, T.; Tsai, J.Y.; Kennedy, T. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest., 2004, 22, 706-712.
225. Xiong, H.Q.; Rosenberg, A.; LoBuglio, A.; Schmidt, W.; Wolff, R.A.; Deutsch, J.; Needle, M.; Abbruzzese, J.L. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J. Clin. Oncol., 2004, 22, 2610-2616.
226. Rocha Lima, C.M.; Savarese, D.; Bruckner, H.; Dudek, A.; Eckardt, J.; Hainsworth, J.; Yunus, F.; Lester, E.; Miller, W.; Saville, W.; Elfring, G.L.; Locker, P.K.; Compton, L.D.; Miller, L.L.; Green, M.R. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J. Clin. Oncol., 2002, 20, 1182-1191.
227. Tedesco, K.L.; Berlin, J.; Rothenberg, M.; Choy, H.; Wyman, K.; Pearson, A.S.; Beauchamp, R.D.; Merchant, N.; Lockhart, A.C.; Shyr, Y.; Caillouette, C.; Chakravarthy, B. A phase I study of concurrent 9-nitro-20(s)-camptothecin (9NC/Orathecin) and radiation therapy in the treatment of locally advanced adenocarcinoma of the pancreas. Radiother. Oncol., 2005, 76, 54-58.
228. Greenway, B.A. Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double blind, placebo controlled trial. BMJ, 1998, 316, 1935-1938.
229. Sherman, W.H.; Fine, R.L. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology, 2001, 60, 316-321.
230. Palmer, D.H.; Stocken, D.D.; Hewitt, H.; Markham, C.E.; Hassan, A.B.; Johnson, P.J.; Buckels, J.A.; Bramhall, S.R. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann. Surg. Oncol., 2007, 14, 2088-2096.
231. Kochi, M.; Fujii, M.; Kanamori, N.; Kaiga, T.; Takahashi, T.; Kobayashi, M.; Takayama, T. Neoadjuvant chemotherapy with S-1 and CDDP in advanced gastric cancer. J. Cancer Res. Clin. Oncol., 2006, 132, 781-785.
232. Mambrini, A.; Sanguinetti, F.; Pacetti, P.; Caudana, R.; Iacono, C.; Guglielmi, A.; Guadagni, S.; Del Freo, A.; Fiorentini, G.; Cantore, M. Intra-arterial infusion of 5-fluorouracil, leucovorin, epirubicin and carboplatin (FLEC regimen) in unresectable pancreatic cancer: results of a ten-year experience. In Vivo, 2006, 20, 751-755.
233. Klinkenbijl, J.H.; Jeekel, J.; Sahmoud, T.; van Pel, R.; Couvreur, M.L.; Veenhof, C.H.; Arnaud, J.P.; Gonzalez, D.G.; de Wit, L.T.; Hennipman, A.; Wils, J. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann. Surg., 1999, 230, 776-782.
234. Talar-Wojnarowska, R.; Malecka-Panas, E. Molecular pathogenesis of pancreatic adenocarcinoma: potential clinical implications. Med. Sci. Monit., 2006, 12, 186-193.
235. Lowenfels, A.B.; Maisonneuve, P. Epidemiology and risk factors for pancreatic cancer. Best Pract. Res. Clin. Gastroenterol., 2006, 20, 197-209.
236. Dergham, S.T.; Dugan, M.C.; Kucway, R.; Du, W.; Kamarauskiene, D.S.; Vaitkevicius, V.K.; Crissman, J.D.; Sarkar, F.H. Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int. J. Pancreatol., 1997, 21, 127-143.
237. Haraguchi, N.; Inoue, H.; Tanaka, F.; Mimori, K.; Utsunomiya, T.; Sasaki, A.; Mori, M. Cancer stem cells in human gastrointestinal cancers. Hum. Cell, 2006, 19, 24-29.
238. König, J.; Hartel, M.; Nies, A.T.; Martignoni, M.E.; Guo, J.; Büchler, M.W.; Friess, H.; Keppler, D. Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int. J. Cancer, 2005, 115, 359-367.
239. Cazap, E.; Mee Kyung, K. In Oncología Clínica. Patología especial.; Gonzalez Baron, M., Ordoñez, A., Feliu, J., Zamora, P., Espinosa, E., de Canto, J. Eds., McGraw-Hill Interamericana: Spain, 1998, pp. 177-189.
240. Cunningham, J.D.; Aleali, R.; Aleali, M.; Brower, S.T.; Aufses, A.H. Malignant small bowel neoplasms: histopathologic determinants of recurrence and survival. Ann. Surg., 1997, 225, 300-306.
241. Fishman, P.N.; Pond, G.R.; Moore, M.J.; Oza, A.; Burkes, R.L.; Siu, L.L.; Feld, R.; Gallinger, S.; Greig, P.; Knox, J.J. Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases. Am. J. Clin. Oncol., 2006, 29, 225-231.
242. Dabaja, B.S.; Suki, D.; Pro, B.; Bonnen, M.; Ajani, J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer, 2004, 101, 518-526.
243. Chaiyasate, K.; Jain, A.K.; Cheung, L.Y.; Jacobs, M.J.; Mittal, V.K. Prognostic factors in primary adenocarcinoma of the small intestine: 13-year single institution experience. World J. Surg. Oncol., 2008, 6, 12.
244. North, J.H.; Pack, M.S. Malignant tumors of the small intestine: a review of 144 cases. Am. Surg., 2000, 66, 46-51.
245. Howe, J.R.; Karnell, L.H.; Menck, H.R.; Scott-Conner, C. The American College of Surgeons Commission on Cancer and the American Cancer Society. Adenocarcinoma of the small bowel: review of the National Cancer Data Base, 1985-1995. Cancer, 1999, 86, 2693-2706.
246. Singh, A.K.; Tierney, R.M.; Low, D.A.; Parikh, P.J.; Myerson, R.J.; Deasy, J.O.; Wu, C.S.; Pereira, G.C.; Wahab, S.H.; Mutic, S.; Grigsby, P.W.; Hope, A.J. A prospective study of differences in duodenum compared to remaining small bowel motion between radiation treatments: implications for radiation dose escalation in carcinoma of the pancreas. Radiat. Oncol., 2006, 1, 33.
247. Gibson, M.K.; Holcroft, C.A.; Kvols, L.K.; Haller, D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist, 2005, 10, 132-137.
248. Jigyasu, D.; Bedikian, A.Y.; Stroehlein, J.R. Chemotherapy for primary adenocarcinoma of the small bowel. Cancer, 1984, 53, 23-25.
249. Tascilar, M.; Loos, W.J.; Seynaeve, C.; Verweij, J.; Sleijfer, S. The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas. Oncologist, 2007, 12, 1351-1360.
250. Akbulut, H.; Soykan, I.; Yakaryilmaz, F.; Icii, F.; Aksoy, F.; Haznedaroglu, S.; Yildirim, S. Five-year results of the treatment of 23 patients with immunoproliferative small intestinal disease: a Turkish experience. Cancer, 1997, 80, 8-14.
251. Robertson, J.H.; Sarkar, S.; Yang, S.Y.; Seifalian, A.M.; Winslet, M.C. In vivo models for early development of colorectal liver metastasis. Int. J. Exp. Pathol., 2008, 89, 1-12.
252. Kavolius, J.; Fong, Y.; Blumgart, L.H. Surgical resection of metastatic liver tumors. Surg. Oncol. Clin. N. Am., 1996, 5, 337-352.
253. Thornton, J.G.; Morris, A.M.; Thornton, J.D.; Flowers, C.R.; McCashland, T.M. Racial variation in colorectal polyp and tumor location. J. Natl. Med. Assoc., 2007, 99, 723-728.
254. Kang, H.; O'Connell, J.B.; Leonardi, M.J.; Maggard, M.A.; McGory, M.L.; Ko, C.Y. Rare tumors of the colon and rectum: a national review. Int. J. Colorectal Dis., 2007, 22, 183-189.
255. Symonds, D.A.; Vickery, A.L. Mucinous carcinoma of the colon and rectum. Cancer, 1976, 37, 1891-1900.
256. Kang, H.; O'Connell, J.B.; Maggard, M.A.; Sack, J.; Ko, C.Y. A 10-year outcomes evaluation of mucinous and signet-ring cell carcinoma of the colon and rectum. Dis. Colon Rectum, 2005, 48, 1161-1168.
257. Psathakis, D.; Schiedeck, T.H.; Krug, F.; Oevermann, E.; Kujath, P.; Bruch, H.P. Ordinary colorectal adenocarcinoma vs. primary colorectal signet-ring cell carcinoma: study matched for age, gender, grade, and stage. Dis. Colon Rectum, 1999, 42, 1618-1625.
258. Nissan, A.; Guillem, J.G.; Paty, P.B.; Wong, W.D.; Cohen, A.M. Signet-ring cell carcinoma of the colon and rectum: a matched control study. Dis. Colon Rectum, 1999, 42, 1176-1180.
259. DiSario, J.A.; Burt, R.W.; Kendrick, M.L.; McWhorter, W.P. Colorectal cancers of rare histologic types compared with adenocarcinomas. Dis. Colon Rectum, 1995, 38, 1227.
260. Modlin, I.M.; Sandor, A. An analysis of 8305 cases of carcinoid tumors. Cancer, 1997, 79, 813-829.
261. Wong, M.T.; Eu, K.W. Primary colorectal lymphomas. Colorectal Dis., 2006, 8, 586-591.
262. Modlin, I.M.; Lye, K.D.; Kidd, M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer, 2003, 97, 934-959.
263. Onaitis, M.W.; Kirshbom, P.M.; Hayward, T.Z.; Quayle, F.J.; Feldman, J.M.; Seigler, H.F.; Tyler, D.S. Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann. Surg., 2000, 232, 549-556.
264. Schneider, T.A.; Birkett, D.H.; Vernava, A.M. Primary adenosquamous and squamous cell carcinoma of the colon and rectum. Int. J. Colorectal Dis., 1992, 7, 144-147.
265. Bernick, P.E.; Klimstra, D.S.; Shia, J.; Minsky, B.; Saltz, L.; Shi, W.; Thaler, H.; Guillem, J.; Paty, P.; Cohen, A.M.; Wong, W.D. Neuroendocrine carcinomas of the colon and rectum. Dis. Colon Rectum, 2004, 47, 163-169.
266. McKenzie, S.; Barnes, S.; Schwartz, R. An update on the surgical management of colon cancer. Curr. Surg., 2005, 62, 313-318.
267. Zaheer, S.; Pemberton, J.H.; Farouk, R.; Dozois, R.R.; Wolff, B.G.; Ilstrup, D. Surgical treatment of adenocarcinoma of the rectum. Ann. Surg., 1998, 227, 800-811.
268. Williams, C.B.; Saunders, B.P.; Talbot, I.C. Endoscopic management of polypoid early colon cancer. World J. Surg., 2000, 24, 1047-1051.
269. Nivatvongs, S. Surgical management of early colorectal cancer. World J. Surg., 2000, 24, 1052-1055.
270. Kosmider, S.; Lipton, L. Adjuvant therapies for colorectal cancer. World J. Gastroenterol., 2007, 13, 3799-3805.
271. Sticca, R.P.; Rodriguez-Bigas, M.; Penetrante, R.B.; Petrelli, N.J. Curative resection for stage I rectal cancer: natural history, prognostic factors, and recurrence patterns. Cancer Invest., 1996, 14, 491-497.
272. Elias, D.; Cavalcanti, A.; Sabourin, J.C.; Lassau, N.; Pignon, J.P.; Ducreux, M.; Coyle, C.; Lasser, P. Resection of liver metastases from colorectal cancer: the real impact of the surgical margin. Eur. J. Surg. Oncol., 1998, 24, 174-179.
273. Desch, C.E.; Benson, A.B. 3rd; Somerfield, M.R.; Flynn, P.J.; Krause, C.; Loprinzi, C.L.; Minsky, B.D.; Pfister, D.G.; Virgo, K.S.; Petrelli, N.J. American Society of Clinical Oncology. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J. Clin. Oncol., 2005, 23, 8512-8519.
274. Kodner, I.J.; Gilley, M.T.; Shemesh, E.I.; Fleshman, J.W.; Fry, R.D.; Myerson, R.J. Radiation therapy as definitive treatment for selected invasive rectal cancer. Surgery, 1993, 114, 850-856.
275. Frykholm, G.J.; Isacsson, U.; Nygård, K.; Montelius, A.; Jung, B.; Påhlman, L.; Glimelius, B. Preoperative radiotherapy in rectal carcinoma-aspects of acute adverse effects and radiation technique. Int. J. Radiat. Oncol. Biol. Phys., 1996, 35, 1039-1048.
276. Willett, C.G.; Fung, C.Y.; Kaufman, D.S.; Efird, J.; Shellito, P.C. Postoperative radiation therapy for high-risk colon carcinoma. J. Clin. Oncol., 1993, 11, 1112-1117.
277. Mendenhall, W.M.; Rout, W.R.; Vauthey, J.N.; Haigh, L.S.; Zlotecki, R.A.; Copeland, E.M. Conservative treatment of rectal adenocarcinoma with endocavitary irradiation or wide local excision and postoperative irradiation. J. Clin. Oncol., 1997, 15, 3241-3248.
278. Mendenhall, W.M.; Amos, E.H.; Rout, W.R.; Zlotecki, R.A.; Hochwald, S.N.; Cance, W.G. Adjuvant postoperative radiotherapy for colon carcinoma. Cancer, 2004, 101, 1338-1344.
279. Benson, A.B. 3rd; Schrag, D.; Somerfield, M.R.; Cohen, A.M.; Figueredo, A.T.; Flynn, P.J.; Krzyzanowska, M.K.; Maroun, J.; McAllister, P.; Van Cutsem, E.; Brouwers, M.; Charette, M.; Haller, D.G. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J. Clin. Oncol., 2004, 22, 3408-3419.
280. Buyse, M.; Zeleniuch-Jacquotte, A.; Chalmers, T.C. Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA, 1988, 259, 3571-3578.
281. O'Connell, M.J.; Martenson, J.A.; Wieand, H.S.; Krook, J.E.; Macdonald, J.S.; Haller, D.G.; Mayer, R.J.; Gunderson, L.L.; Rich, T.A. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N. Engl. J. Med., 1994, 331, 502-507.
282. Moertel, C.G.; Fleming, T.R.; Macdonald, J.S.; Haller, D.G.; Laurie, J.A.; Goodman, P.J.; Ungerleider, J.S.; Emerson, W.A.; Tormey, D.C.; Glick, J.H. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med., 1990, 322, 352-358.
283. Budd, G.T.; Fleming, T.R.; Bukowski, R.M.; McCracken, J.D.; Rivkin, S.E.; O'Bryan, R.M.; Balcerzak, S.P.; Macdonald, J.S. 5-Fluorouracil and folinic acid in the treatment of metastatic colorectal cancer: a randomized comparison. A Southwest Oncology Group Study. J. Clin. Oncol., 1987, 5, 272-277.
284. Comella, P.; Palmieri, G.; Lorusso, V.; Catalano, G.; Nicollela, D.; Ianniello, G.P.; Casaretti, R.; Montella, M.; Frasci, G.; Perna, M.; Comella, G. Double biochemical modulation of 5-fluorouracil by methotrexate and levo-folinic acid in the treatment of advanced digestive tract malignancies. Eur. J. Cancer, 1996, 32, 1719-1726.
285. Cunningham, D. Mature results from three large controlled studies with raltitrexed ('Tomudex'). Br. J. Cancer, 1998, 77, 15-21.
286. Twelves, C.; Wong, A.; Nowacki, M.P.; Abt, M.; Burris, H. 3rd; Carrato, A.; Cassidy, J.; Cervantes, A.; Fagerberg, J.; Georgoulias, V.; Husseini, F.; Jodrell, D.; Koralewski, P.; Kröning, H.; Maroun, J.; Marschner, N.; McKendrick, J.; Pawlicki, M.; Rosso, R.; Schüller, J.; Seitz, J.F.; Stabuc, B.; Tujakowski, J.; Van Hazel, G.; Zaluski, J.; Scheithauer, W. Capecitabine as adjuvant treatment for stage III colon cancer. N. Engl. J. Med., 2005, 352, 2696-2704.
287. André, T.; Boni, C.; Mounedji-Boudiaf, L.; Navarro, M.; Tabernero, J.; Hickish, T.; Topham, C.; Zaninelli, M.; Clingan, P.; Bridgewater, J.; Tabah-Fisch, I.; de Gramont, A. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon
288. Saltz, L.B.; Cox, J.V.; Blanke, C.; Rosen, L.S.; Fehrenbacher, L.; Moore, M.J.; Maroun, J.A.; Ackland, S.P.; Locker, P.K.; Pirotta, N.; Elfring, G.L.; Miller, L.L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N. Engl. J. Med., 2000, 343, 905-914.
289. Hurwitz, H.; Fehrenbacher, L.; Novotny, W.; Cartwright, T.; Hainsworth, J.; Heim, W.; Berlin, J.; Baron, A.; Griffing, S.; Holmgren, E.; Ferrara, N.; Fyfe, G.; Rogers, B.; Ross, R.; Kabbinavar, F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350, 2335-2342.
290. Rothenberg, M.L.; Eckardt, J.R.; Kuhn, J.G.; Burris, H.A. 3rd; Nelson, J.; Hilsenbeck, S.G.; Rodriguez, G.I.; Thurman, A.M.; Smith, L.S.; Eckhardt, S.G.; Weiss, G.R.; Elfring, G.L.; Rinaldi, D.A.; Schaaf, L.J.; Von Hoff, D.D. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J. Clin. Oncol., 1996, 14, 1128-1135.
291. Cunningham, D.; Humblet, Y.; Siena, S.; Khayat, D.; Bleiberg, H.; Santoro, A.; Bets, D.; Mueser, M.; Harstrick, A.; Verslype, C.; Chau, I.; Van Cutsem, E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med., 2004, 351, 337-345.
292. Van Cutsem, E.; Peeters, M.; Siena, S.; Humblet, Y.; Hendlisz, A.; Neyns, B.; Canon, J.L.; Van Laethem, J.L.; Maurel, J.; Richardson, G.; Wolf, M.; Amado, R.G. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J. Clin. Oncol., 2007, 25, 1658-1664.
293. Martenson, J.A. Jr; Willett, C.G.; Sargent, D.J.; Mailliard, J.A.; Donohue, J.H.; Gunderson, L.L.; Thomas, C.R. Jr; Fisher, B.; Benson, A.B. 3rd; Myerson, R.; Goldberg, R.M. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J. Clin. Oncol., 2004, 22, 3277-3283.
294. Mariadason, J.M.; Arango, D.; Shi, Q.; Wilson, A.J.; Corner, G.A.; Nicholas, C.; Aranes, M.J.; Lesser, M.; Schwartz, E.L.; Augenlicht, L.H. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res., 2003, 63, 8791-8812.
295. Fong, Y.; Fortner, J.; Sun, R.L.; Brennan, M.F.; Blumgart, L.H. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg., 1999, 230, 309-318.
296. Sarmiento, J.M.; Que, F.G. Hepatic surgery for metastases from neuroendocrine tumors. Surg. Oncol. Clin. N. Am., 2003, 12, 231-242.
297. van Vilsteren, F.G.; Baskin-Bey, E.S.; Nagorney, D.M.; Sanderson, S.O.; Kremers, W.K.; Rosen, C.B.; Gores, G.J.; Hobday, T.J. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival. Liver Transpl., 2006, 12, 448-456.
298. Adson, M.A.; van Heerden, J.A.; Adson, M.H.; Wagner, J.S.; Ilstrup, D.M. Resection of hepatic metastases from colorectal cancer. Arch. Surg., 1984, 119, 647-651.
299. Leonard, G.D.; Brenner, B.; Kemeny, N.E. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J. Clin. Oncol., 2005, 23, 2038-2048.
300. Fidler, I.J.; Wilmanns, C.; Staroselsky, A.; Radinsky, R.; Dong, Z.; Fan, D. Modulation of tumor cell response to chemotherapy by the organ environment. Cancer Metastasis Rev., 1994, 13, 209-222.
301. Kemeny, N.; Huang, Y.; Cohen, A.M.; Shi, W.; Conti, J.A.; Brennan, M.F.; Bertino, J.R.; Turnbull, A.D.; Sullivan, D.; Stockman, J.; Blumgart, L.H.; Fong, Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med., 1999, 341, 2039-2048.
302. Rougier, P.; Laplanche, A.; Huguier, M.; Hay, J.M.; Ollivier, J.M.; Escat, J.; Salmon, R.; Julien, M.; Roullet, Audy, J.C.; Gallot, D. Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J. Clin. Oncol., 1992, 10, 1112-1118.
303. McGinn, C.J.; Lawrence, T.S. Clinical results of the combination of radiation and fluoropyrimidines in the treatment of intrahepatic cancer. Semin. Radiat. Oncol., 1997, 7, 313.
304. Inokuchi, M.; Uetake, H.; Shirota, Y.; Yamada, H.; Tajima, M.; Sugihara, K. Gene expression of 5-fluorouracil metabolic enzymes in primary colorectal cancer and corresponding liver metastasis. Cancer Chemother. Pharmacol., 2004, 53, 391-396.
305. Moser, C.; Lang, S.A.; Kainz, S.; Gaumann, A.; Fichtner-Feigl, S.; Koehl, G.E.; Schlitt, H.J.; Geissler, E.K.; Stoeltzing, O. Blocking heat shock protein-90 inhibits the invasive properties and hepatic growth of human colon cancer cells and improves the efficacy of oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol. Cancer Ther., 2007, 6, 2868-2878.
306. Kulke, M.H.; Mayer, R.J. Carcinoid tumors. N. Engl. J. Med., 1999, 340, 858-868.
307. Sutcliffe, R.; Maguire, D.; Ramage, J.; Rela, M.; Heaton, N. Management of neuroendocrine liver metastases. Am. J. Surg., 2004, 187, 39-46.
308. Le Treut, Y.P.; Delpero, J.R.; Dousset, B.; Cherqui, D.; Segol, P.; Mantion, G.; Hannoun, L.; Benhamou, G.; Launois, B.; Boillot, O.; Domergue, J.; Bismuth, H. Results of liver transplantation in the treatment of metastatic neuroendocrine tumors. A 31-case French multicentric report. Ann. Surg., 1997, 225, 355-364.
309. Taal, B.G.; Hoefnagel, C.A.; Valdes Olmos, R.A.; Boot, H.; Beijnen, J.H. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J. Clin. Oncol., 1996, 14, 1829-1838.
310. Forrer, F.; Valkema, R.; Kwekkeboom, D.J.; de Jong, M.; Krenning, E.P. Neuroendocrine tumors. Peptide receptor radionuclide therapy. Best Pract. Res. Clin. Endocrinol. Metab., 2007, 21, 111-129.
311. Diaco, D.S.; Hajarizadeh, H.; Mueller, C.R; Fletcher, W.S.; Pommier, R.F.; Woltering, E.A. Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intraarterial chemotherapy, and hepatic arterial chemoembolization. Am. J. Surg., 1995, 169, 523-528.
312. Siperstein, A.E.; Rogers, S.J.; Hansen, P.D.; Gitomirsky, A. Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases. Surgery, 1997, 122, 1147-1154.
313. Giovannini, M. Percutaneous alcohol ablation for liver metastasis. Semin. Oncol., 2002, 29, 192-195.
314. Rivera, E.; Ajani, J.A. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am. J. Clin. Oncol., 1998, 21, 36-38.
315. Link, K.H.; Aigner, K.R.; Kuehn, W.; Schwemmle, K.; Kern, D.H. Prospective correlative chemosensitivity testing in high-dose intraarterial chemotherapy for liver metastases. Cancer Res., 1986, 46, 4837-4840.